New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: croscarmellose sodium gelatin indigo carmine iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

endeva medical pty ltd - 10969 - compression unit, intermittent - external calf compression to improve venous blood flow back to heart. this is a mobile device and should be used whenever walking, sitting or bed resting during the day or after operation.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 33.06mg equivalent to cinacalcet 30 mg - film coated tablet - 30 mg - active: cinacalcet hydrochloride 33.06mg equivalent to cinacalcet 30 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 66.12mg equivalent to cinacalcet 60 mg - film coated tablet - 60 mg - active: cinacalcet hydrochloride 66.12mg equivalent to cinacalcet 60 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 99.18mg equivalent to cinacalcet 90 mg - film coated tablet - 90 mg - active: cinacalcet hydrochloride 99.18mg equivalent to cinacalcet 90 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - amoxicillin trihydrate 91.84 mg/ml equivalent to amoxicillin 80 mg/ml; potassium clavulanate 27.154 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 11.40 mg/ml. +5% overage);   - powder for oral suspension - active: amoxicillin trihydrate 91.84 mg/ml equivalent to amoxicillin 80 mg/ml potassium clavulanate 27.154 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 11.40 mg/ml. +5% overage)   excipient: citric acid colloidal silicon dioxide dispersible cellulose mannitol sodium citrate sucralose tutti frutti flavour 051880 ap0551 vanilla xanthan gum - amoxiclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. amoxiclav is indicated for the short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. susceptibility to amoxiclav will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with amoxiclav susceptible betalactamase-producing organisms may therefore be treated by amoxiclav.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml; potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage);   - powder for oral suspension - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage)   excipient: citric acid colloidal silicon dioxide dispersible cellulose mannitol sodium citrate sucralose tutti frutti flavour 051880 ap0551 vanilla xanthan gum - amoxiclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. amoxiclav is indicated for the short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. susceptibility to amoxiclav will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with amoxiclav susceptible betalactamase-producing organisms may therefore be treated by amoxiclav.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - diclofenac sodium 1 mg/ml - eye drops, solution - 0.3 mg/0.3ml - active: diclofenac sodium 1 mg/ml excipient: boric acid polyoxyl 35 castor oil trometamol water for injection - diclofenac devatis 0.1% (1 mg/ml) eye drops, unit-dose eye drops are indicated for: · post-operative inflammation in cataract surgery and other surgical interventions. · prevention of cystoid macular oedema after cataract extraction with lens implantation. · post-traumatic inflammation in non-penetrating wounds. · inhibition of miosis in cataract surgery. · relief of pain and photophobia. · non-infected inflammatory conditions of the anterior segment of the eye.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phenindione, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; citric acid; magnesium stearate - indications as at 01 jan 1991 : for the prophylaxis and treatment of thrombosis, embolism and thrombophlebitis. particularly useful in venous thromboembolism.

Australia - English - Department of Health (Therapeutic Goods Administration)

endeva medical pty ltd - 63241 - alternating-pressure bed mattress system - the purpose of this mattress is to prevent pressure injuries.